their risk of developing AD and memory impairment. Genome-wide association studies (GWAS) have identified single-nucleotide polymorphisms (SNPs), or common genetic variants, that are associated with hallmark pathological biomarkers of AD such as beta-amyloid plaques in the brain and phosphorylated tau in the cerebrospinal fluid (CSF). 8, 9 These studies have provided important insight into biological pathways associated with AD; however, the link between PCC metabolic decline and vulnerability to AD is poorly understood. Decline in PCC metabolism correlates well with disease progression. By contrast, amyloid deposition measured with positron emission tomography (PET), appears less sensitive to disease progression. 10, 11 As such, decline in PCC metabolism over time may provide distinct and important insights into biological mechanisms underlying the disease. The primary aim of this study was to discover SNPs associated with longitudinal decline in PCC glucose metabolism that affect the (1) risk of developing AD and (2) progression of the disease (ie, cognitive decline). Although the pathways linking PCC glucose metabolic decline to AD remain unknown, there is substantial evidence supporting a role for abnormal glucose regulation in AD. Cellular uptake of glucose is closely regulated by oxidative stress signaling pathways. 12 Furthermore, impaired oxidative stress signaling has been shown to lead to reduced glucose metabolism and the eventual development of memory impairment in AD. 13 Therefore, genes involved in adaptation to oxidative stress or the regulation of glucose metabolism may contribute to PCC metabolic decline and disease vulnerability. Given that the PCC is the first and most pronounced region to undergo metabolic decline, PCC metabolism is a powerful and unexplored endophenotype for investigating unknown genetic contributions to AD. Fludeoxyglucose F 18 ([ 18 F] FDG) PET measures the uptake of glucose into neurons and astrocytes and can be used as a proxy for neuronal activity. Thus, in order to achieve these aims, we performed a quantitative trait GWAS of longitudinal decline in PCC glucose metabolism, as measured by [ 18 F] FDG PET imaging in the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. Our top candidate from the GWAS was then explored further to determine its effects on AD risk, decline in cognitive performance over time, and gene expression in brain.
Patients and Methods

Participant Details
Participants included in the original imaging GWAS were part of the ADNI (http://www.adni.loni.usc.edu). We restricted the analysis to participants who were white with European ancestry.
Individuals included in the imaging GWAS had [ 18 F] FDG
PET data available at two time points at least a year apart. This included a total of 606 ADNI participants (mean age of 74 years 6 7.1 [standard deviation] mean education of 16 years 6 2.8, 43.7% APOE*4 carriers, and 37.8% female; Table 1 ). Participants for the analysis of conversion to MCI or AD and of longitudinal cognitive change were from the National Alzheimer's Coordinating Centre (NACC). [14] [15] [16] This is a data set including healthy elderly and AD participants with longitudinal clinical and cognitive data ( Table 2) . Participants for the brain RNA sequencing (RNA-Seq) analysis were part of the MAYO RNA-Sequencing study 17 and the Rush Memory and Aging Project (MAP) 18 /Religious Orders Study (ROS). 19 These are data sets with RNA-Seq transcript data and genotype data for healthy and AD participants (Table 2) . For the analysis of conversion to MCI or AD, we included healthy participants at baseline from NACC who had longitudinal clinical data and genotype data available (n 5 870) in order to track their conversion over time (mean age of 74.9 years 6 8.8, mean education of 16 years 6 8.8, 28% APOE*4 carriers, and 59.2% female). For the longitudinal cognitive change analysis, we included all NACC participants who had longitudinal cognitive data at two time points at least a year apart and available genotype data (n 5 851). All of the participants for this analysis overlapped with the participants included in the conversion analysis. For the RNA-Seq analysis, we used two data sets from ROS/MAP and MAYO which provide RNA-Seq data from the dorsolateral prefrontal cortex and temporal cortex, respectively. For ROS/MAP, we included all participants with available dorsolateral prefrontal cortex (DLPFC) RNA-Seq data and genotype data (n 5 220, mean age of death 84.4 6 4.5, mean education of 16.7 6 3.4, 25.9% APOE*4 carriers, and 66.4% female). For the MAYO data set, we included all participants with available temporal cortex RNA-Seq data and genotype data (n 5 159, mean age of death 80.3 6 7.8, 32.9% APOE*4 carriers, and 55% female). All participants provided written informed consent, and the protocols were approved by their Participants in NACC were used as an independent data set to examine, respectively, the effect of significant SNPs obtained from the GWAS in ADNI on (1) risk of conversion to MCI or AD as assessed by the clinical diagnosis at each visit and (2) disease progression (ie, longitudinal cognitive performance). RNA-Seq data from DLPFC were also available for participants in the ROS and MAP studies and in participants from the MAYO study, and these were used to test the functional impact of significant SNPs on brain transcript expression levels.
Genotyping and Imputation
ADNI GWAS data were downloaded from the ADNI database. Genotyping in ADNI was performed using blood DNA samples with three genotyping arrays: Illumina 610-Quad, Illumina-OmniExpress, or Illumina HumanOmni2.5-4v1 as previously described. 21 Genotype data underwent standard quality control including identity checks, cryptic relatedness (identity-by-descent > 0.0625), sample exclusion for call rate <95%, SNP exclusion for call rate <95%, Hardy-Weinberg equilibrium (HWE) of p < 1 3 10 26 , and minor allele frequency (MAF) < 1%. Unlinked SNPs (linkage disequilibrium [LD] pruning at r 2 5 0.1) passing the quality control criteria were used to determine the first 10 principal components for population structure using EIGENSTRAT 22 and to remove population structure outliers. Imputation was performed using IMPUTE2 software, using the European population from the 1000 Genomes Project, Phase 3 as a reference panel. 23 After imputation, we excluded SNPs with an info quality score <0.9, MAF < 0.05, and HWE (p < 5 3 10 26 ). This yielded a total of 2,820,932 SNPs for the GWAS analysis. A subset of ADNI subjects (n 5 818) was also whole-genome sequenced, and available data were used to confirm the results obtained from SNP imputation. VCF files were annotated using SNPeff 24 and analyzed by PLINK 1.9. 25 GWAS data were also used for obtaining the genotype information for significant SNP(s) in our follow-up analyses. These data sets also underwent the same quality-control pipeline and imputation described above.
Quantification and Statistical Analysis
GWAS. The GWAS was performed using PLINK software. The analysis was run using a linear regression under the assumption of an additive genetic model. Covariates included baseline age, sex, education, disease status, and the first three principal components for population structure. We did not include APOE*4 as a covariate in the initial GWAS, because of the colinearity between disease status and APOE*4 dosage. The suggestive association threshold was p < 1 3 10 25 , and the threshold for genome-wide significance was p < 5 3 10 28 . This is a more conservative, consensus threshold for genome-wide significance based on correction for 1 million independent tests. 26 We aimed to discover SNPs passing the genome-wide significant threshold. Manhattan plots and QQ plots were generated using the package "qqman" in R (version 3.3.1; R Foundation for Statistical Computing, Vienna, Austria). Regional association plot was created using LocusZoom.
COMPETING RISKS REGRESSION ANALYSIS. We ran a competing risks regression analysis developed by Fine and Gray to evaluate the risk of conversion to MCI or AD by genotype (of significant SNPs), while accounting for death as a competing risk. 27 This analysis was carried out using the "cmprsk" package in R. 28 Competing risks analysis is a type of time-toevent analysis that aims to accurately estimate the marginal probability of an event in the presence of competing events such as death. This approach is relevant in this study because the participants are elderly and death may occur before the event of interest (ie, conversion to MCI or AD) is observed, which can produce bias in risk estimates. We included all participants from the NACC data set who were healthy at baseline, had genotyping data available, and had at least 1 year of follow-up to assess the effect of significant SNPs on risk of conversion. Age at entry, APOE*4 status, sex, and education were included as covariates in the analysis (n 5 870; Table 1 ). Disease was not included as a covariate because all participants were healthy at baseline.
LINEAR MIXED-EFFECTS ANALYSIS OF LONGITUDINAL
COGNITION. We tested the association between significant SNPs and longitudinal change in cognitive performance using participants from the NACC data set who had longitudinal neuropsychological testing data available (n 5 851). We used the Logical Memory Delayed Recall Score (out of 25) to assess episodic memory, the Boston Naming Task (BNT; out of 30) to assess language, and the Mini Mental State Examination (MMSE; out of 30) to assess global cognitive function. These tests are known to be sensitive measures of cognitive decline in AD and were acquired longitudinally in the NACC data set. We tested all participants (n 5 851) who were healthy at baseline who had available genotype information. We analyzed the data using a linear mixed-effects model implemented in R, testing for the association between genotype and the change in cognitive performance over time, that is, a time by genotype interaction. This model accounts for correlations among repeated measurements within each participant, and permits varying observation periods and varying rates of decline among individuals. In addition to genotype, the time of measurement, and the interaction between these two variables, we included age at baseline, APOE*4 dosage, final diagnosis, education, and sex as covariates.
RNA-SEQ ANALYSIS. We tested whether transcript expression was altered between AD cases and controls for genes containing significant SNPs from the GWAS. We then tested the effect of significant SNPs on transcript expression of genes of interest using the ROS/MAP and MAYO RNA-Seq data sets from DLPFC tissue and temporal cortex tissue, respectively. We used the general linear model implemented in R to perform a regression analysis looking at the effect of genotype on transcript expression for genes containing significant hits in the GWAS. All analyses included age at death, APOE*4 status, sex, disease status, postmortem interval (PMI), and education (not available in the MAYO data set) as covariates. We removed outliers greater than 2 absolute standard deviations from the mean to exclude the possibility of sampling errors. We also examined two large publicly available online peripheral blood gene expression data sets to test whether significant SNPs modified gene expression in blood (https://eqtl.onderzoek.io/index.php?page=info & http://genenetwork.nl/bloodeqtlbrowser/).
Data and Software Availability
GWAS data and [
18 F] FDG PET imaging data used in the present study were retrieved through ADNI (http://adni.loni.usc. edu). GWAS data sets for follow-up competing risks regression and linear mixed-effects analyses were retrieved through NIAG-ADS (https://www.niagads.org) [ADC1 (NG00022), ADC2 (NG00023), ADC3 (NG00024)] for the NACC participants and [ROSMAP (NG00029)] for the ROS/MAP participants. Clinical and cognitive visit data for the NACC participants were obtained by request from the longitudinal uniform data set (RDD-UDS). RNA-Seq data in ROS/MAP participants and MAYO participants were obtained from Sage Bionetwork's Synapse project (https://www.synapse.org, syn3388564).
Results
GWAS Identifies a Variant in PPP4R3A Associated With Decline in PCC [
18 F] FDG PET There was a total of 606 ADNI participants included in the GWAS for PCC decline. Participants included a mixture of 192 healthy adults, 335 MCI patients, and 79 AD patients.
We identified 130 SNPs that passed the suggestive association threshold (Fig 1B; Supplementary Table 1 ). These SNPs corresponded to nine loci on seven separate chromosomes. Only one SNP passed the genome-wide significance threshold (5 3 10
28
). This was rs2273647, an intronic variant located in the gene, PPP4R3A (OMIM*610351, on chr. 14q32.12; Fig 1B; Fig 2B) . We generated a Q-Q plot to compare the observed versus the expected p values for the GWAS. The genomic inflation factor k was equal to 1.00, indicating that there is no systemic inflation of the observed p values in our data set. The minor allele of rs2273647-T demonstrated a protective effect on PCC glucose metabolic decline, with the homozygous minor allele group showing the least reduction in PCC glucose metabolism followed by the heterozygous group, and the homozygous wild-type groups (Fig 2B) . We determined that rs2273647 was an imputed SNP. Therefore, we checked the concordance rate between rs2273647 genotype in individuals who had whole-genome sequencing data in ADNI. There was a 98% concordance rate between rs2273647 genotype and whole-genome sequencing data in ADNI, confirming the validity of imputation for rs2273647.
There were 274 individuals who were homozygous wild type (C/C), 266 who were heterozygous (C/T), and 66 who were homozygous recessive (T/T) at rs2273647 (Table 3 ). There were no significant differences in baseline age, education, sex, or disease status between the three genotypes groups. There was a significant difference in the proportion of APOE*4 carriers versus noncarriers (p 5 0.011) across rs2273647 genotype groups. When the GWAS was rerun to include APOE*4 status as a covariate in addition to the original covariates, the effect of rs2273647-T remained quite strong (p 5 1.67 3 10
27
). 
PPP4R3A rs2273647-T Affects Risk of Conversion to MCI or AD
We aimed to assess whether the significant SNP was associated with risk of clinical conversion from healthy aging to MCI or AD. In order to evaluate the risk by genotype, we performed a competing risks regression analysis with death as the competing risk. Participants from the NACC data set who were healthy controls at baseline had longitudinal clinical visit data and had available genotype information were included in the analysis (Table 1, Table 4 ; n 5 870). These subjects are independent from those used in the ADNI GWAS. For the 870 participants included in the analysis, the mean duration of follow-up was 4.3 years and the maximal follow-up time was 7 years. Risk of conversion was considered the risk of conversion from healthy to MCI or from healthy directly to AD (whichever conversion came first). Genotype was coded using an additive model (by dosage of the minor allele). Genotype for rs2273647 was significantly associated with risk of conversion to MCI or AD in 870 healthy controls. The minor allele (T) dosage was significantly associated with a reduced probability of developing MCI or AD (Fig 3A; hazard ratio [HR] 5 0.76; p 5 0.038; n 5 870). Although the difference in risk between the heterozygote and homozygote T allele carriers was small, there was a more dramatic difference in the risk of conversion between the carriers and noncarriers of the T-allele characteristic of a dominant effect. Therefore, we also ran the competing risks regression using a dominant model (ie, minor allele carriers [CT and TT] vs noncarriers [CC] ). There was a significant dominant effect on risk of conversion (Fig 3B; HR 5 0.70; p 5 0.041; n 5 870), with T-allele carriers demonstrating a significantly lower risk compared to noncarriers.
To reduce the risk of bias attributed to the inclusion of individuals with a very short duration of followup, we restricted the analysis to those participants who had a minimum of 2 and 3 years of follow-up in separate analyses and tested both the additive and dominant models. When we restricted the sample to those with a minimum of 2 years of follow-up (n 5 735; mean follow-up time of 4.8 years), there was a significant additive effect of genotype on risk of conversion (HR 5 0.72; p 5 0.01; n 5 735) and an even stronger dominant effect on risk of conversion (HR 5 0.58; p 5 0.0014; n 5 735).
When we restricted the sample to those with a minimum of 3 years of follow-up (n 5 635; mean follow-up time of 5.2 years), genotype was no longer significantly associated with risk of conversion for the additive model (p 5 0.13); however, there was a strong significant association between genotype and risk of conversion for the dominant model (HR 5 0.63; p 5 0.006; n 5 635). These results suggest that genotype has a consistent and significant impact on the risk of developing disease. When comparing models, the dominant model provided a better model fit with lower Bayesian information criterion. Therefore, we used a dominant model as the default for the remainder of the follow-up analyses and reported additive model results as well.
PPP4R3A rs2273647-T Affects Longitudinal Cognitive Performance
Next, we aimed to assess the relationship between the PPP4R3A variant and cognitive performance over time.
We performed a linear mixed-effects analysis on all NACC participants to assess the association between rs2273647-T and the change in cognitive performance (memory, language and global cognition) over time, by evaluating time by rs2273647 interaction. All participants who were healthy at baseline had longitudinal cognitive data, and genotype data available were included in the model and classified according to final diagnosis (n 5 819 for BNT, n 5 822 for MMSE, and n 5 854 for Logical Memory Delayed Recall). Our analysis showed that cognitive decline was modified by the genotype of rs2273647, with significant interaction for time by genotype observed on both BNT (p 5 1.37 3 10
26
) and MMSE (p 5 3.41 3 10
215
) in individuals with a final diagnosis of AD ( Fig 4A,B) ; the extent of cognitive decline over time was reduced among individuals with the T allele in rs2273647 versus wild-type homozygotes, demonstrating its protective effect on cognitive performance. The results were also significant when using the additive model, for both the time by genotype effect on BNT (p < 0.05) and MMSE (p < 5 3 10
26
). All effects were significant after controlling for age at baseline, APOE*4 dosage, final diagnosis, education, and sex as covariates.
There were no significant time by genotype interactions in individuals with a final diagnosis of healthy or MCI, whose cognitive performance remained relatively stable over time (Fig 4A,B) . There were no significant interactions in any of the three groups on longitudinal logical memory (Fig 4C) .
PPP4R3A rs2273647-T Affects Gene Expression
Last, we wanted to assess whether PPP4R3A transcript expression is altered in disease and whether rs2273647-T has a functional impact on gene expression. First, we identified the most highly expressed transcripts in brain FIGURE 3: The minor allele (T) of rs2273647 in PPP4R3A is associated with reduced risk of conversion to MCI or AD. (A) Cumulative incidence functions demonstrating the risk of conversion to MCI or AD for three genotypes of rs2273647 over a 7-year time period using an additive model. T allele dosage was significantly associated with the risk of conversion to MCI or AD over time after controlling for APOE*4 status, age at entry, sex and education (HR 5 0.76; p 5 0.038; n 5 870). (B). Cumulative incidence functions demonstrating the risk of conversion to MCI or AD using a dominant model. T-allele carriers demonstrate significantly lower risk of conversion to MCI or AD over time after controlling for APOE*4 status, age at entry, sex and education (HR 5 0.70; p 5 0.041; n 5 870). AD 5 Alzheimer's disease; HR 5 hazard ratio; MCI 5 mild cognitive impairment.
tissue for PPP4R3A. There were two transcripts that were fully annotated, protein coding and expressed in brain: ENST00000554684 and ENST00000555462. The mean expression in FPKM (fragments per kilobase of transcript per million mapped reads) of ENST00000554684 in DLPFC and temporal cortex tissue was 1.41 (60.89) and 28.59 (65.34), respectively. The mean expression in FPKM of ENST00000555462 in DLPFC and temporal cortex was 1.39 (60.65) and 4.77 (60.98), respectively. First, we aimed to test whether there were differences in the expression of PPP4R3A between AD cases and healthy controls in the RNA-Seq data sets from DLPFC and temporal cortex ( Table 2, Table 5 ). We found a significant difference between cases and controls in ENST00000554684 expression after controlling for age at death, sex, APOE*4 status, and PMI. The healthy controls demonstrated lower expression compared to AD (Fig 5B; p 5 0.0038; n 5 159), suggesting that transcript expression of this gene is altered by disease. There were no significant differences between AD and healthy controls within DLPFC tissue for either transcript.
Next, we aimed to assess whether rs2273647 genotype is associated with altered transcript expression. The rs2273647-T genotype was associated with lower PPP4R3A ENST00000555462 transcript expression in temporal cortex of healthy control participants from the MAYO data set, with carriers of the minor allele demonstrating lower transcript expression compared to noncarriers (Fig 5A; p 5 0.011; n 5 159). Our results were also significant when using an additive model (p 5 0.015). There was no significant difference in expression of this isoform in AD participants. Furthermore, there was no effect of genotype on transcript expression in the DLPFC tissue from the ROS/MAP data set.
Finally, we took advantage of two, large, web-based expression quantitative trait loci (eQTL) datasets to test the effect of rs2273647-T dose on PPP4R3A expression in peripheral blood. Results in these data sets are only available for the additive model. We found that rs2273647 was an eQTL, lowering the expression of PPP4R3A in blood with increasing dosage of the minor allele in a large meta-analysis of nine data sets including 5,311 samples (p 5 4.75 3 10
210
; Z5 -6.23). 29 We were able to confirm this result in a second blood eQTL data set of 4,896 participants of European ancestry (p 5 2.53 3 10
; https://eqtl.onderzoek.io), providing further support for the involvement of this variant in modifying gene expression in blood. 30 
Discussion
Previous GWAS studies using imaging markers including hippocampal atrophy, beta-amyloid, and CSF tau have provided insight into the mechanisms underlying genetic vulnerability to AD, implicating a number of genes associated with these AD endophenotypes. 8, 9, 21, 31 The significant advantage of using PCC metabolic decline as an endophenotype in the present study is that it is a consistent early biomarker for AD that has been shown to correlate well with disease progression, to a greater extent than beta-amyloid deposition. 10, 11 Thus, using it as an endophenotype has the potential to reveal important genes that are closely associated with the mitigation (or exacerbation) of disease progression.
In this study, we demonstrate that rs2273647-T is associated with less metabolic decline in the PCC, a reduced risk of conversion to MCI or AD, and reduced cognitive decline. Previous studies have tested for associations between known AD risk variants and imaging markers of AD progression, including PCC hypometabolism 32 ; however, this is the first study to identify a novel genome-wide association between a common variant and longitudinal PCC metabolic decline. Taken together, these results suggest that the T allele confers a protective advantage by preserving brain glucose uptake in the face of AD pathology. We show that rs2273647-T is associated with a reduced risk of conversion to MCI or AD, suggesting that PPP4R3A plays a role in predisposition to disease. We also show that rs2273647-T is protective against language and global cognitive decline, in those individuals who progress to AD over their follow-up period. The lack of significant interaction effects in those who remain healthy or convert to MCI in our study is likely attributed to the fact that many of these participants remained healthy for a large proportion of the study and do not show substantial decline regardless of genotype (as is apparent in Fig  4) , thus obscuring the effect of rs2273647-T. Our findings demonstrate a strong protective effect in those individuals who convert to AD, especially against global cognitive decline, emphasizing that individuals carrying rs2273647-T perform better despite the onset of disease.
In order to provide a functional link between PPP4R3A at the molecular level and the clinical level, we aimed to assess whether rs2273647 genotype was significantly associated with PPP4R3A transcript expression. We were able to detect a significant effect of genotype in healthy controls for one of the protein-coding transcripts in temporal cortex, whereby healthy control carriers demonstrated lower transcript expression. We also demonstrated that transcript expression is significantly lower in healthy controls compared to AD, providing further evidence that PPP4R3A is altered in disease. The reason for healthy control carriers demonstrating lower transcript expression, but not AD participants, is unclear; however, it is possible that the effect of disease on transcript expression outweighs the effect of the protective genotype. The lack of replication of these results in the DLPFC may be attributed to a regional effect of rs2276347 on transcript expression within the temporal cortex, which is more strongly affected by AD progression. Gene expression changes appear to be triggered by the onset of AD-associated pathology, which is present earlier and to a greater extent in the temporal cortex than in the frontal cortex. Further work will be needed to determine the regionally specific effects of rs2273647 on gene expression in the brain.
In previous work, PPP4R3A was shown to be involved in gluconeogenesis. Furthermore, reduced expression of PPP4R3A was directly linked to lower fasting blood glucose levels, whereas increased PPP4R3A expression was linked to insulin resistance. 33 This strongly suggests that PPP4R3A plays an important role in influencing glucose uptake in humans, and that increased PPP4R3A expression may be detrimental. More tellingly, the SNP identified here has been associated with reduced fasting blood glucose levels (b 5 -0.015; p 5 1.7 3 10
24
). 34 Furthermore, we confirmed that it is an eQTL in blood in two independent data sets, significantly reducing gene expression in T-allele carriers. 29, 30 Taking this into consideration with our findings, rs2273647-T carriers may have reduced gene expression and reduced fasting blood glucose levels, which could contribute directly to a protective effect on [ 18 F] FDG decline. Conversely, higher expression of PPP4R3A may result in insulin resistance and reduced brain glucose uptake, which has been linked to AD. 12, 35 Another possibility is that T-allele carriers experience a lower risk for diabetes as a result of their differential glucose regulation, thus indirectly affecting AD risk and brain metabolic decline. 36 Reduced brain glucose uptake is an early marker of neurodegeneration, and not necessarily specific to AD. Therefore, it is possible that PPP4R3A may influence vulnerability to multiple neurodegenerative diseases. 37 Although the exact mechanism of action of PPP4R3A in AD is unknown, abnormal regulation of insulin signaling and glucose metabolism is associated with greater oxidative stress, and thus PPP4R3A may play a role in the predisposition of neuronal cells to oxidative damage and metabolic dysfunction associated with neurodegenerative disease pathology. Interestingly, smk-1 (PPP4R3A ortholog) has been shown to play a direct role in mediating longevity through the insulin-signaling pathway. 38, 39 Furthermore, accumulating evidence suggests that the effective regulation of insulin signaling promotes healthy aging and is protective against toxic age-related protein aggregation, including amyloid-beta. [40] [41] [42] Thus, alterations in PPP4R3A may help slow the onset and accumulation of AD pathology through the modification of insulin-signaling pathways. In a follow-up search for previous associations between PPP4R3A and AD risk, we found that a distinct variant in PPP4R3A passed the suggestive threshold for association with risk of AD in a familybased GWAS, lending additional support for the involvement of this gene in AD. 43 Further investigations will be needed to identify the protective mechanisms by which PPP4R3A affects disease vulnerability. One limitation to our study is that we have not been able to determine definitively whether the true biological effect of rs2273647-T is dominant or additive. As is conventionally done in GWAS studies, we identified this variant in our initial analysis with an additive model. We observed in the follow-up analyses, however, that the effect of genotype on disease risk, progression, and gene expression was stronger when rs2273647 genotype was classified according to a dominant model. We therefore returned to the original GWAS and checked the p value of our SNP assuming a dominant model and found that it remains quite significant at p 5 1.32 3 10
27
. On balance, our results support an additive model with the dominant model appearing stronger mainly in those analyses (such as gene expression in brain) with smaller sample sizes and relatively few homozygous recessive subjects.
In conclusion, we identify a novel protective variant in the gene PPP4R3A associated with reduced glucose metabolic decline. We were able to replicate the protective effect in an independent data set, demonstrating that the minor allele at rs2273647 is associated with a reduced risk of developing AD and a slower rate of cognitive decline in subjects who ultimately develop AD. Importantly, our findings strongly support a role for PPP4R3A in AD vulnerability and progression. Furthermore, this variant affects PPP4R3A gene expression, indicating a functional effect. Although the specific biological pathways underlying the role of PPP4R3A in AD vulnerability require further investigation, the results reported here suggest that PPP4R3A should be considered as a potential therapeutic target in AD.
